A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

Phase 1 Completed 47 enrolled AstraZeneca

RandomizedParallel-groupDouble-blindBasic science

Summary

This is a two-part multiple dose study in healthy male and female (of non-child bearing potential) elderly volunteers, and in Alzheimer's disease patients, to assess the safety, effects on the body, and blood, CSF, and urine drug levels of AZD3293. AZD3293 is being developed for the treatment of Alzheimer's Disease

Timeline

Start: 2013-03
Primary completion: 2014-03
Completion: 2014-03

Publications

Cebers G, Lejeune T, Attalla B, Soderberg M, Alexander RC, Budd Haeberlein S, Kugler AR, Ingersoll EW, Platz S, Scott CW. Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair. J Prev Alzheimers Dis. 2016;3(4):202-218. doi: 10.14283/jpad.2016.119.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lanabecestat	Small molecule	5 mg	Oral
Subject	Lanabecestat	Small molecule	150 mg	Oral

Indications

No indication recorded.